Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Watching VIQ Solutions; Zacks Small-Cap Research Sets $3.20 Price Valuation

Watching VIQ Solutions; Zacks Small-Cap Research Sets $3.20 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_03152023_VQS_Marin.pdf

byHappy Mohamed

March 15, 2023

1 minute read

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_03152023_VQS_Marin.pdf

Analyst Ratings

8 Analysts Have This to Say About Workday

By Benzinga Insights

November 29, 8:04 AM

Workday (NASDAQ:WDAY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

WDAY

News
Tech

Rivian To Fix Wrong Software Mishap With New OTA Update, Says No Physical Repairs Required

By Anan Ashraf

November 16, 12:27 AM

EV makerÂ Rivian Automotive Inc (NASDAQ:RIVN) will roll out a new over-the-air update for customers after the previous update…

RIVN

Why Is Dycom Industries Stock Surging Premarket Wednesday?

By Lekha Gupta

May 22, 9:06 AM

Dycom Industries' Contract revenue increased 9.3% Y/Y to $1.142 billion, beating the consensus of $1.093 billion. EPS of $2.12 surpassed the street view of $1.51.

AIRR

Affimed Announces Oral Presentation Of Phase 1/2 Data From AFM13 In Combination With Allogeneic NK Cells At The 2023 ASH Annual Meeting

By Benzinga Newsdesk

November 2, 9:24 AM

In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a 72.2% complete

AFMD

Watching VIQ Solutions; Zacks Small-Cap Research Sets $3.20 Price Valuation

Related Posts

8 Analysts Have This to Say About Workday

Rivian To Fix Wrong Software Mishap With New OTA Update, Says No Physical Repairs Required

Why Is Dycom Industries Stock Surging Premarket Wednesday?

Affimed Announces Oral Presentation Of Phase 1/2 Data From AFM13 In Combination With Allogeneic NK Cells At The 2023 ASH Annual Meeting